Tessera
Folgen

Alessio Gerussi

@aleger87.bsky.social

Hepatologist and Assistant Professor at University of Milano-Bicocca. Interested in autoimmune liver disease and AI.

8 Posts31 Follower21 Folgt
NEJM.org@nejm.org · 10mo ago

The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which the authors review. Learn more: nej.md/4hwZMgj #MedSky #GastroSky

Review Article Noninvasive Assessment of Liver Fibrosis Laurent Castera, M.D., Ph.D., Mary E. Rinella, M.D., and Emmanuel A. Tsochatzis, M.D., Ph.D. A figure showing the diagnosis, staging, and progression of liver fibrosis. The NEJM identity sits at the bottom.
Alessio Gerussi@aleger87.bsky.social · last yr.

🔥 HOTSPoT sets a new benchmark in liver pathology: open-source, accurate, and externally validated tool for portal tract segmentation. A brilliant team effort led by Giorgio Cazzaniga — whose vision and drive made it possible 👏 rdcu.be/ew7qh #AI #Digitalpathology

Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model

npj Digital Medicine - Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model

rdcu.be

NEJM AI@ai.nejm.org · last yr.

This article analyzes how nonexperts perceive AI-generated medical advice, finding that it is often rated as accurate as — or better than — doctor responses, raising concerns about overreliance and potential harm from incorrect guidance. Full article: nejm.ai/43xKDG0 #AI #MedSky #MLSky

People Overtrust AI-Generated Medical Advice despite Low Accuracy

This article presents a comprehensive analysis of how artificial intelligence (AI)–generated medical responses are perceived and evaluated by nonexperts. We conducted a study in which a total of 30...

nejm.ai

NEJM.org@nejm.org · last yr.

In the SELECT-GCA phase 3 trial involving patients with giant-cell arteritis, the oral Janus kinase inhibitor upadacitinib (15 mg) significantly improved remission of disease, with less glucocorticoid use. Full trial results: nej.md/3XBdkia #MedSky

A graph showing the time to first flare of giant-cell arteritis through week 52.